Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;34(10):2805-2808.
doi: 10.1038/s41375-020-0953-3. Epub 2020 Jul 3.

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

Francesca Palandri  1 , Alfonso Piciocchi  2 , Valerio De Stefano  3 , Massimo Breccia  4 , Guido Finazzi  5 , Alessandra Iurlo  6 , Paola Fazi  2 , Stefano Soddu  2 , Bruno Martino  7 , Sergio Siragusa  8 , Francesco Albano  9 , Francesco Passamonti  10 , Marco Vignetti  2   4 , Alessandro M Vannucchi  11
Affiliations
Comment

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

Francesca Palandri et al. Leukemia. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Start of cytoreductive therapies in ET and PV patients (a) and start of ruxolitinib in MF and PV patients during the COVID-19 pandemic (b). HU hydroxyurea, IFN interferon, ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis. Survey data were collected and managed using the REDCap electronic data capture tools hosted at the GIMEMA Foundation. Most responders have >10 years of clinical experience on MPNs and >20 patients in annual follow-up for each disease. However, only 10.9% of the clinicians directly followed MPN patients affected by COVID-19.
Fig. 2
Fig. 2
Management of COVID-19 screening before (a) or during (b) ruxolitinib and management of ruxolitinib in case of mild (c) or moderate (d) COVID-19 infection. Mild infection: respiratory symptoms not requiring hospitalization. Moderate infection: hypoxia (SPO2 ≤94%) requiring ventilatory support but not mechanical ventilation.
See this image and copyright information in PMC

Comment on

References

    1. von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno F, Hirsch HH. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia. 2020;34:1487–94. doi: 10.1038/s41375-020-0832-y. - DOI - PMC - PubMed
    1. La Rosée F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020:1–10. - PMC - PubMed
    1. Elli EM, Barate C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib. Front Oncol. 2019;9:1186. doi: 10.3389/fonc.2019.01186. - DOI - PMC - PubMed
    1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. doi: 10.1182/blood-2016-03-643544. - DOI - PubMed
    1. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69. doi: 10.1038/s41375-018-0077-1. - DOI - PMC - PubMed